Author:
Uğraklı Muzaffer,Koçak Mehmet Zahid,Dinç Gülhan,Genç Tuğrul Burak,Çağlayan Melek,Uğraklı Selin,Hendem Engin,Er Muhammed Muhiddin,Çağlayan Dilek,Eryılmaz Melek Karakurt,Araz Murat,Geredeli Çağlayan,Tatlı Ali Murat,Eren Orhan Önder,Artaç Mehmet
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference32 articles.
1. Ariel H, Cooke JP (2019) Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc J 15(3):214
2. Aybay C, Imir T, Okur H (1995) The effect of omeprazole on human natural killer cell activity. General Pharmacol Vascul Syst 26(6):1413–1418
3. Çağlayan D, Koçak MZ, Geredeli Ç, Tatli AM, Göksu SS, Eryilmaz MK, Araz M, Artaç M (2022) The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. Europ J Clin Pharmacol 79(2):1–6
4. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368–1379
5. Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski A, Arbour K, Chaft J (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29(6):1437–1444